Carilax Tablet
Carisoprodol
250mg
Incepta Pharmaceuticals Ltd.
| Pack size | 30's Pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 6.00 AED |
Indications
Carilax Tablet is used for:
Painful muscle spasm associated with musculoskeletal conditions
Adult Dose
Oral
Painful muscle spasm associated with musculoskeletal conditions
Adult: The recommended dose is 250 mg to 350 mg three times a day and at bedtime for up to 2-3 wk.
Child Dose
Musculoskeletal Conditions
<16 years: Not recommended
>16 years: 250-350 mg q8hr and HS
Renal Dose
Renal impairment: Caution; not studied
Administration
May be taken with or without food.
Contra Indications
Acute intermittent porphyria, hypersensitivity. Lactation.
Precautions
Due to sedative properties, may impair ability to perform hazardous tasks such as driving or operating machinery
Additive sedative effects when used with other CNS depressants including alcohol
Cases of abuse, dependence and withdrawal
Seizures
Pregnancy-Lactation
Pregnancy
Data over many decades of use of drug in pregnancy have not identified drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes; data on meprobamate, the primary metabolite of carisoprodol, do not show consistent association between maternal use and increased risk of major birth defects
Lactation
Data from published literature report that carisoprodol and its metabolite, meprobamate, are present in breastmilk; there are no data on effect on milk production; there is one report of sedation in an infant who was breastfed by a mother taking carisoprodol; because there have been no consistent reports of adverse events in breastfed infants over decades of use, the developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant or from underlying maternal condition; infants exposed to drug through breast milk should be monitored for sedation
Interactions
CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) - additive sedative effects
Potentially Fatal: Potentiates alcohol and other CNS depressants.
Contraindicated (0)
Serious (24)
apalutamide
benzhydrocodone/acetaminophen
buprenorphine subdermal implant
buprenorphine transdermal
buprenorphine, long-acting injection
calcium/magnesium/potassium/sodium oxybates
fentanyl
fentanyl intranasal
fentanyl iontophoretic transdermal system
fentanyl transdermal
fentanyl transmucosal
hydrocodone
lonafarnib
methohexital
metoclopramide intranasal
oliceridine
olopatadine intranasal
opicapone
remifentanil
selinexor
sodium oxybate
sufentanil SL
tolcapone
zuranolone
Adverse Effects
Side effects of Carisoprodol :
>10%
Drowsiness (13-17%)
1-10%
Dizziness (7-8%),Headache (3-5%)
Frequency Not Defined
Orthostatic hypotension,Syncope,Tachycardia,Agitation,Irritability,Depression,Allergic/idiosyncratic reactions (pruritus, rash, dizziness, etc),Epigastric distress,N/V,Facial flushing,Weakness
Mechanism of Action
Carisoprodol blocks interneuronal synaptic activity in the descending reticular formation and spinal cord resulting in skeletal muscle relaxation.
Note
Carilax 250mg Tablet manufactured by Incepta Pharmaceuticals Ltd.. Its generic name is Carisoprodol. Carilax is availble in Bangladesh.
Farmaco BD drug index information on Carilax Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.